BullFrog AI Partners With the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog AI Holdings, Inc. recently announced a strategic partnership with the Sage Group, a leader in the provision of strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical device, biotech, regenerative medicine, and cell and gene therapy fields.
The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the company’s preclinical prodrug asset. The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources, and network of contacts, including innovators and large pharma.
“Glioblastoma is one of the deadliest forms of cancer, with a 5-year survival rate of less than 7%,” said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage Group’s support, we look forward to identifying the right partner to help us advance clinical development of our oncology programs globally in an effort to bring a revolutionary new treatment option to glioblastoma patients.”
The market for glioblastoma treatment is expected to surpass $10 billion by 2030, up from $5.1 billion in 2020, according to a 2022 analysis by a Vision Research Report. BullFrog AI has previously announced the grant of exclusive licenses from JHU for a novel formulation of mebendazole that has been evaluated in two clinical trials for glioblastoma, and for a novel prodrug of mebendazole with improved bioavailability.
BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need. For more information, visit www.bullfrogai.com.
Total Page Views: 1301
